Why the study?
The risk and treatment of endocarditis with the Harmony transcatheter pulmonary valve remain unclear.
Case Report (n=1)
No
Surgical explantation of the Harmony transcatheter pulmonary valve is feasible but complex, highlighting the need to factor potential future explantation into initial valve selection.
May warrant factoring explantation complexity into initial Harmony valve selection; leaves open need for prospective data.
BACKGROUND: The Harmony (Medtronic) self-expanding transcatheter pulmonary valve is the first Food and Drug Administration-approved transcatheter valve system designed to treat severe pulmonary regurgitation (PR) in patients with a native or surgically repaired right ventricular outflow tract. The valve greatly expands transcatheter interventions to patients with residual PR after childhood surgical interventions; the risk and treatment of endocarditis with this therapy are still unclear. SUMMARY: In this report, we describe to our knowledge the first published details and images of surgical explantation of this valve with an extensive skirt extending into the right ventricular outflow tract myocardium and pulmonary artery. DISCUSSION: Dissection was difficult and significantly more complex than removal of a standard surgical valve, but it was safely achieved. TAKE-HOME MESSAGE: This case illustrates that although less invasive therapies have intrinsic benefits avoiding repeat open surgery, there may be tradeoffs with more complex surgical explantation that must be factored into timing and selection of valves.
No takes yet. Share an insight, caveat, or question.
Gregg et al. (2025) conducted a case report in Harmony transcatheter pulmonary valve endocarditis in repaired Tetralogy of Fallot (n=1). Surgical explantation of Harmony transcatheter pulmonary valve was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: